Lifestyle Features

Scholar Rock gets first FDA nod for rare muscle-wasting disease

The U.S. Food and Drug Administration approved Scholar Rock's therapy on Friday to treat a rare genetic condition that causes muscle weakness, marking the first regulatory approval for the ‌company.

Scholar Rock gets first FDA nod for rare muscle-wasting disease

Most Recent

.js-only { display: none; } .queue_story .image_box:before, #loadMoreStories, .browseday { display: none; }

AstraZeneca's breast cancer pill fails in late-stage trial

AstraZeneca's breast cancer pill fails in late-stage trial

Christy Santhosh, Reuters | Updated Sept. 11 - 4:31 p.m. | Save Story

AstraZeneca's breast cancer pill failed to meet the main goal of improving progression-free survival in a late-stage trial, the company said on Friday, a week after the treatment received U.S. approval.

AbbVie's menstrual migraine treatment meets late-stage study goal

AbbVie's menstrual migraine treatment meets late-stage study goal

Reuters | Updated Sept. 10 - 9:14 a.m. | Save Story

AbbVie said on Thursday its migraine treatment had in a late-stage study reduced the migraine days associated ‌with the menstrual period.

US FDA reports 22 cases of salmonella infections linked to broccoli sprouts

US FDA reports 22 cases of salmonella infections linked to broccoli sprouts

Reuters | Updated Sept. 10 - 9:07 a.m. | Save Story

The U.S. Food and Drug Administration said on Wednesday it was investigating a multistate outbreak of salmonella infections linked to broccoli sprouts, the latest in a series of foodborne-illness investigations ‌involving produce.

Evommune scraps eczema drug after trial miss, shares plunge

Evommune scraps eczema drug after trial miss, shares plunge

Reuters | Updated Sept. 9 - 9:12 a.m. | Save Story

Evommune said on Tuesday it will not advance its experimental skin disease drug after it failed to meet the main goal in ‌a mid-stage trial, sending its shares down 24% in aftermarket ⁠trading.

Weight Watchers names Stephen Bye as CEO

Weight Watchers names Stephen Bye as CEO

Reuters | Updated Sept. 9 - 8:48 a.m. | Save Story

WW International on Wednesday named Stephen Bye as its chief executive officer, effective this ‌fall.

Roivant's experimental lung disease drug meets goals in mid-stage study

Roivant's experimental lung disease drug meets goals in mid-stage study

Sahil Pandey, Reuters | Updated Sept. 9 - 3:23 a.m. | Save Story

Roivant said on Tuesday its experimental drug met the main goals of a mid-stage study in patients with high blood pressure associated with a type of lung disease, sending shares up ‌about 17%.

Amgen-AstraZeneca lung cancer drug combo boosts survival in late-stage trial

Amgen-AstraZeneca lung cancer drug combo boosts survival in late-stage trial

Reuters | Updated Sept. 8 - 2:26 p.m. | Save Story

Amgen's targeted immunotherapy, Imdelltra, combined with AstraZeneca's cancer drug Imfinzi, significantly improved overall survival in patients with extensive-stage small-cell lung cancer in a late-stage trial, the companies said on ‌Tuesday.

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

Sriparna Roy, Reuters | Updated Sept. 8 - 1:24 p.m. | Save Story

Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis' treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns about the prospects of similar therapies for the tough-to-treat rare ‌disease.

Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study

Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study

Sneha S K, Reuters | Updated Sept. 8 - 12:03 p.m. | Save Story

Inhibrx Biosciences said on Tuesday its experimental combination cancer drug helped reduce tumors in a mid-stage study in patients with a type of head and neck cancer.

Is summer heat hurting your trees? The fix may be less water, not more

Is summer heat hurting your trees? The fix may be less water, not more

David Een, KSL | Posted Sept. 8 - 12:02 p.m. | Save Story

Utah's intense summer heat can leave trees looking scorched, tired, or unhealthy, but the solution is not always more water. Learn how proper deep, infrequent watering, soil care, and mulch can help trees better handle late-summer stress.

Sandoz bets big on biosimilars, aims to double group sales by 2035

Sandoz bets big on biosimilars, aims to double group sales by 2035

Bhanvi Satija and Marleen Kaesebier, Reuters | Updated Sept. 8 - 11:18 a.m. | Save Story

Swiss drugmaker Sandoz aims to more than double its annual net sales by 2035, with a majority coming from biosimilar medicines, the company said at its capital markets day on Tuesday.

Novartis twin drug trial setbacks pile pressure on pipeline, CEO

Novartis twin drug trial setbacks pile pressure on pipeline, CEO

Bhanvi Satija, Dave Graham and Marleen Kaesebier, Reuters | Updated Sept. 8 - 11:14 a.m. | Save Story

Novartis said on Tuesday its experimental drug for a muscle-wasting disorder failed a late-stage study, the second major trial setback in days, sending the Swiss drugmaker's shares down about 11% in its worst trading day on record.

AI healthcare platform Forus valued at $3 billion in latest funding round

AI healthcare platform Forus valued at $3 billion in latest funding round

Reuters | Updated Sept. 8 - 9:33 a.m. | Save Story

AI healthcare platform Forus said on Tuesday it has raised $150 million in a funding round that valued the company at $3 billion, ‌tripling its valuation in about four months.

Grasshopper populations low in Utah, but homeowners should stay prepared

Grasshopper populations low in Utah, but homeowners should stay prepared

David Een, KSL | Updated Sept. 8 - 9:26 a.m. | Save Story

Grasshopper populations were expected to be high in Utah after a mild winter, but numbers have been surprisingly low across much of the state. Learn why grasshopper outbreaks are difficult to predict and what homeowners can do now to prepare for future infestations.

Pharvaris' genetic disorder drug meets main goal in late-stage trial

Pharvaris' genetic disorder drug meets main goal in late-stage trial

Kunal Das, Reuters | Updated Sept. 8 - 8:36 a.m. | Save Story

Pharvaris said on Tuesday its experimental oral drug helped prevent swelling attacks in patients with hereditary angioedema, meeting the main goal of a late-stage trial.

Bristol Myers' blood cancer cell therapy succeeds in mid-stage trial

Bristol Myers' blood cancer cell therapy succeeds in mid-stage trial

Reuters | Updated Sept. 8 - 7:10 a.m. | Save Story

Bristol Myers Squibb said on Tuesday its experimental cell therapy showed a high overall response rate in a mid-stage trial, in patients with a hard-to-treat form of blood ‌cancer.

Utahns flock to Millcreek Canyon for affordable Labor Day getaway

Utahns flock to Millcreek Canyon for affordable Labor Day getaway

VideoAnnette Campbell, KSL | Updated Sept. 8 - 6:39 a.m. | Save Story

Cooler temperatures on Monday drew hikers, bikers and families to Millcreek Canyon for one last summer outing before fall approaches.

Waves of layoffs are sweeping across Utah. Here's what workers losing their jobs should know

Waves of layoffs are sweeping across Utah. Here's what workers losing their jobs should know

Art Raymond, Deseret News | Posted Sept. 7 - 9:01 p.m. | Save Story

While job cuts are down, the growth rate of the U.S. employment sector has also slowed — and Utahns are not immune. Here's what to know if you're one of those without a job.

25 years later, 9/11 responders are still dying from illnesses tied to the attacks

25 years later, 9/11 responders are still dying from illnesses tied to the attacks

John Domen, WTOP | Updated Sept. 7 - 8:28 p.m. | Save Story

The Sept. 11, 2001, attacks killed thousands of people in a matter of hours. Nearly 25 years later, illnesses tied to response efforts continue claiming lives. More than 400 FBI employees have been diagnosed, and dozens have died.